[1]Dennis, E.A.; Smythies, L.E.; Grabski, R.; Li, M.; Ballestas, M.E.;Shimamura, M.; Sun, J.J.; Grams, J.; Stahl, R.;Niederweis, M.E.; et al. Cytomega-lovirus promotes intestinal macrophage-mediated mucosal inflammation throughinduction of Smad7. Mucosal Immunol. 2018, 11, 1694–1704.
[2]Yokoyama, Y .; Yamakawa, T.; Hirano, T.; Kazama, T.; Hirayama, D.;Wagatsuma, K.; Nakase, H. Current Diagnostic and Therapeutic Approaches to Cytomegalovirus Infections in Ulcerative Colitis Patients Basedon Clinical and Ba-sic Research Data. Int. J. Mol. Sci. 2020, 21, 2438.
[3]Shoaei P,Shojaei H,Jalali M,et al.Clostridium difficile isolated from faecalsamples in patients with ulcerative colitis.BMC Infect Dis.2019;19(1):361.
[4] Aletaha N, Dadvar Z, Salehi B, Ketabi Moghadam P, Niksirat A, JowkarA, Taslimi R, Allameh SF, Ebrahimi Daryani N. Clinical and Pathological Features of Ulcerative Colitis in Patients with and without Clostridium Difficile Infection;An Observational Study. Middle East J Dig Dis. 2019 Jan;11(1):17-23.
[5]Sambuelli AM,Negreira SM,Gil AH,et al.Multidrug resistance gene(MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis.Acta Gastroenterol Latinoam. 2006;36(1):23-32.
[6]Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit-riskassessment of golimumab in the treatment of refractory ulcerative colitis. Drug HealthcPatient Saf. 2016;8:1-7.
[7]Bolin TD,Wong S,Crouch R,Engelman JL,Riordan SM.Appendicectomyas a therapy for ulcerative proctitis.Am J Gastroenterol 2009;104(10):2476-82.
[8]Bageacu S,Coatmeur O,Lemaitre JP,Lointier P,Del Tedesco E,Phelip JM,et al.Appendicectomy as a potential therapy for refractory ulcerative proctitis.Ali-ment Pharmacol Ther 2011;34(2):257-8.
[10] Shukla T, Singh S, Loftus EV Jr, Bruining DH, McCurdy JD. AntiviralTherapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015;21(11):2718-2725.
[11] Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I,Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B,Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020 Mar;52(3):268-273.
